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ABSTRACT 
Objective Ciclosporin and infliximab have demonstrated short-term similar efficacy as second-line therapies in 
patients with acute severe UC (ASUC) refractory to intravenous steroids. The aim of this study was to assess 
long-term outcome of patients included in a randomised trial comparing ciclosporin and infliximab. Design 
Between 2007 and 2010, 115 patients with steroid-refractory ASUC were randomised in 29 European centres to 
receive ciclosporin or infliximab in association with azathioprine. Patients were followed until death or last news 
up to January 2015. Colectomy-free survival rates at 1 and 5 years and changes in therapy were estimated 
through Kaplan-Meier method and compared between initial treatment groups through log-rank test. Results 
After a median follow-up of 5.4 years, colectomy-free survival rates (95% CI) at 1 and 5 years were, 
respectively, 70.9% (59.2% to 82.6%) and 61.5% (48.7% to 74.2%) in patients who received ciclosporin and 
69.1% (56.9% to 81.3%) and 65.1% (52.4% to 77.8%) in those who received infliximab (p=0.97). Cumulative 
incidence of first infliximab use at 1 and 5 years in patients initially treated with ciclosporin was, respectively, 
45.7% (32.6% to 57.9%) and 57.1% (43.0% to 69.0%). Only four patients from the infliximab group were 
subsequently switched to ciclosporin. Three patients died during the follow-up, none directly related to UC or its 
treatment. Conclusions In this cohort of patients with steroid-refractory ASUC initially treated by ciclosporin or 
infliximab, long-term colectomy-free survival was independent from initial treatment. These long-term results 
further confirm a similar efficacy and good safety profiles of both drugs and do not favour one drug over the 
other. 
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Trial registration number EudraCT: 2006-005299-42; ClinicalTrials.gouv number: NCT00542152; post-
results. 
 
Significance of this study 
What is already known on this subject? 
►   In patients with acute severe UC refractory to intravenous steroids, ciclosporin and infliximab are efficient 
second-line therapies to avoid emergent colectomy. 
►   Both drugs have similar short-term efficacy and good safety profile. 
►   Few long-term data comparing both drugs are available so far. 
What are the new findings? 
►   Long-term colectomy-free survival is independent from initial second-line treatment. 
►   Higher proportion of patients initially treated with ciclosporin needed a new treatment than those who 
received infliximab first. 
►   Nearly half of patients firstly treated with ciclosporin will switch within 1 year to infliximab. 
►   Bridge therapy with ciclosporin to thiopurine was successful on long term in half of patients. 
How might it impact on clinical practice in the foreseeable future? 
►   Whatever the drug started as rescue therapy in patients with steroid-refractory acute severe UC, long-term 
colectomy rates are similar. 
►   Choice between both drugs should not only be guided by efficacy and safety criteria that are close. 
►   Costs, administration route and patient's preference should also be taken into account in daily practice. 
 
INTRODUCTION 
UC is a lifelong IBD that could be complicated by acute   severe   flare   in   20%-25%   of  patients.
1 2 
Nowadays, acute severe UC (ASUC) remains a life-threatening condition, with 1%-2% death rate in Western 
countries
3 4
 requiring an emergent management in specialised units. 
Most recent guidelines recommend using Truelove-Witts criteria to identify patients with ASUC who should 
receive high doses of intravenous steroids at admission.
5 6
 However, approximately 40% of patients do not 
respond adequately to this regimen.
6
 To avoid colectomy, controlled trials have demonstrated the efficacy of 
both ciclosporin, a calcineurine inhibitor, and infliximab, an anti-tumor necrosis factor (TNF) monoclonal 
antibody, as second-line medical therapy
5 7-9
 
Two trials have directly compared ciclosporin and infliximab in patients with steroid-refractory ASUC. A 
European open-label randomised study (CYSIF) including 115 patients could not demonstrate any superiority of 
intravenous ciclosporin over a standard induction infliximab regimen.
10
 More recently, in a comparative 
pragmatic trial (CONSTRUCT) that enrolled 270 patients in UK, the quality-adjusted survival over 12-36 
months was similar to both agents.
11
 Overall, ciclosporin and infliximab provided high rates of early clinical 
response, over 80% within the first week, with acceptable safety profiles. 
Little is known about the long-term outcome of ASUC in patients receiving such second-line medical therapies 
and few long-term data comparing both drugs are available so far. The aim of this study was to assess long-term 
outcome of patients included in the CYSIF trial. 
PATIENTS AND METHODS  
Initial study design and patients 
CYSIF was a randomised, open-label, 98-day controlled trial conducted from June 2007 to August 2010 in 23 
French and Belgian GETAID (Groupe d'Etude sur les Affections Inflammatoires Digestives) and 6 European 
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ECCO (European Crohn and Colitis Organisation) centres. The institutional review board at each centre 
approved the protocol, and all patients provided written informed consent. Characteristics of the 115 patients 
included and results of the initial study have been previously published in extenso.
10
 
Eligible patients were adults admitted for ASUC defined by a Lichtiger score >10, who were refractory to high-
dose intravenous steroid therapy (at least 0.8 mg/kg/day of methylprednisolone or equivalent) given for at least 5 
days. They were naive for ciclosporin, infliximab and thiopurine except if it was started <4 weeks before 
inclusion. Patients with indication for emergent colectomy, proctitis, Crohn's disease, active infection or usual 
contraindication to ciclosporin, infliximab and thiopurine were excluded. 
To summarise the study design, at day 0 (inclusion visit) randomisation assigned patients to receive ciclosporin, 
administered by continuous intravenous infusion at the initial dose regimen of 2 mg/kg/day, or infliximab at the 
dose of 5 mg/kg. Treatments were not blinded to patients and investigators. In patients from both groups with 
clinical response at day 7, steroids were switched orally and rapidly tapered according to a standardised regimen, 
and azathioprine was started at 2-2.5 mg/kg/day or continued for patients still on. In the same time and according 
to the randomisation arm, intravenous ciclosporin was switched orally or two additional infliximab infusions at 
the same dose were administered at days 14 and 42. Primary endpoint of the trial was treatment failure at any 
time, defined by the presence of at least one of the following criteria: absence of clinical response at day 7, 
relapse between days 7 and 98, absence of steroid-free remission at day 98 or severe adverse event leading to 
treatment interruption, colectomy or death.
10
 
Study period ended at day 98 for patients who completed the trial. Since the end of the study, patients were 
treated according to clinical need as judged by their treating physician. Drugs used were those usually employed 
in UC, according to licensed or published doses and frequency. 
Data update 
Data from patients included in the initial study were updated retrospectively through a standardised form from 
day 98 for patients who completed the study period and from date of early termination for the others. Regimen 
and duration of treatments received since inclusion (ciclosporin or infliximab and azathioprine) were recorded. 
The following events and their date were collected: rescue therapy in case of non-primary response (defined by 
the absence of clinical response at day 7 or disease relapse within the study period), disease relapse in case of 
primary response to ciclosporin or infliximab (defined by recurrence of disease symptoms beyond the study 
period with a need for systemic treatment excluding 5-amino-salicylate acid (ASA) and/or topical therapies), 
colectomy (type of surgery, postoperative complication within 30 days and number of surgical steps) and death. 
Outcomes and follow-up 
Follow-up started at the time of inclusion into the CYSIF trial. The following events were studied per treatment 
group, as given at inclusion into the trial: (1) death; (2) colectomy; (3) first use of any additional UC systemic 
treatment—including steroids, ciclosporin, infliximab and azathioprine or biologics and, excluding 5-ASA; (4) 
first switch to infliximab for patients receiving initially ciclosporin and vice versa; (5) first use of a new systemic 
treatment other than those given at inclusion, allowing ciclosporin and/or azathioprine discontinuation and restart 
in patients receiving ciclosporin, infliximab and/or azathioprine discontinuation and restart and infliximab 
optimisation in those receiving infliximab. In patients who experienced an event, time-to-event was the time 
interval between the beginning of the follow-up and event occurrence. In patients who did not experience any 
event, follow-up was censored at the date of point (1 January 2015) or at the date of last news, whatever occurred 
first. 
Statistical analysis 
Patient characteristics were described through frequency (proportion) or median (IQR). In the general description 
of the patient follow-up, time durations were expressed as median (IQR), except in groups of four patients or less 
in which values or range were provided. 
Cumulative incidence of first use of an additional UC systemic treatment, of first switch to infliximab for 
patients receiving initially ciclosporin and of first use of a new systemic treatment other than those given at 
inclusion which estimates the marginal probability of the event
12
 was calculated taking into account death or 
colectomy whatever occurred first as a competing event, and described through percentage and 95% CI, number 
of events, number of death or colectomy and number of patients at risk at prespecified time points after inclusion 
Published in : Gut (2017) 
Status : Postprint (Author’s version) 
 
into the trial. Cumulative incidence curves were compared between treatment groups through Gray's test and 
difference expressed through absolute risk regression (ARR) estimate and 95% CI.
13
 
Colectomy-free survival curves were derived through the Kaplan-Meier method and described through the 
number of events/number of patients, percentage and 95% CI and number of patients at risk at prespecified time 
points after inclusion into the trial. Colectomy-free survival curves were compared between treatment groups 
through the log-rank test and difference expressed through HR estimate and 95% CI. 
RESULTS 
Study population at inclusion 
Patients were recruited for the initial study in 29 centres in France, Spain, Belgium and Finland from June 2007 
to August 
2010. Among the 115 randomised patients, 58 patients were assigned to receive ciclosporin and 57 to infliximab. 
As two patients from the infliximab arm have received ciclosporin instead of the treatment allocated by 
randomisation, due to patient's wish in one case and to an error of administration in the other, 60 patients actually 
received ciclosporin and 55 infliximab in the initial study and were considered for the present follow-up. 
Baseline characteristics according to treatment received at inclusion in the initial study are shown in table 1. 
They were similar in both groups including endoscopic activity, except for median Lichtiger score and median C 
reactive protein (CRP) level which were significantly higher in patients who received infliximab, but median 
Mayo score and proportion of patients with CRP level above 50 mg/L were not. 
 
Table 1    Demographic and clinical characteristics of the 115 patients 
Characteristic Ciclosporin (n=60) Infliximab (n=55) p Value 
Female gender, n (%) 28 (47) 27 (49) 0.79 
Median age, years (IQR) 39 (26-50) 36 (26-51) 0.48 
Median disease duration, years (IQR) 2.5 (0.5-7.3) 0.8 (0.1-4.4) 0.07 
First attack of UC, n (%) 10 (17) 16 (29) 0.11 
Disease location E3,
18
 n (%) 34 (57) 31 (56) 0.93 
Patient naive to azathioprine, n (%) 56 (93) 51 (93) 0.90 
Median intravenous, steroid duration, days (IQR) 7 (6-9)* 8 (6-9)t 0.72 
Median Lichtiger score (IQR) 12 (11-13) 13 (12-14) 0.004 
Median Mayo disease activity index (IQR) 10 (10-11) 11 (10-11) 0.26 
Mayo endoscopic subscore=3, n (%) 57 (95) 53 (96) 0.73 
Median CRP (mg/L, IQR) 30 (16-66)‡ 46 (28-73)† 0.044 






UC location according to the Montreal classification
18
 (E1 : n=O). 
CRP, C reactive protein. 
 
Description of follow-up 
The median follow-up time was 5.4 years (IQR: 4.7-6.2). 
Among the 60 patients who started ciclosporin at inclusion (figure 1A), there were 34 failures, 24 successes and 
2 lost to follow-up in the initial study. All patients discontinued ciclosporin at the end of the study period and 
received maintenance with azathioprine alone. Among the 34 failures, 5 patients underwent directly colectomy 
after 0.4 (0.2-0.8) months, 21 received rescue therapy after 1 (0.3-3.2) month (2 were treated with steroids and 
19 with infliximab—5 mg/kg in all except one patient who received 10 mg/kg) and 8 did not receive rescue 
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therapy. Among the 19 patients who received infliximab rescue therapy after ciclosporin failure, 10 underwent 
colectomy after 3 (1-8) months (including three with dose intensification), 1 was lost to follow-up 50 months 
after rescue, 1 died (case detailed below) and the remaining 7 patients (including the 2 who received steroids as 
rescue therapy) reached end of follow-up with no new event 56 (43-71) months after rescue. Among the 8 
patients with ciclosporin failure who did not receive rescue therapy, 1 reached end of follow-up 60 months after 
inclusion without new systemic treatment and 7 had new systemic treatment 8 (4-20) months after inclusion: 5 
treated with infliximab reached end of follow-up 57 (45-67) months after treatment and 2 treated by either   
steroids or infliximab underwent colectomy 4 and 25 months later. Among the 24 patients who received 
ciclosporin successfully treated at the end of the study period, 9 had new systemic treatments 6 (4-29) months 
after inclusion: 2 underwent colectomy 2 and 17 months later despite infliximab rescue, and 7 received various 
medical therapies (1 infliximab, 1 steroids, 1 steroids then infliximab, 1 golimumab, 3 infliximab then 
adalimumab) and were still followed up 53 (41-72) months later. Among the 15 patients without new treatment, 
2 died (cases detailed below) and 13 reached end of follow-up 69 (54-82) months after inclusion. 
 
Figure 1    Flowchart of patients according to the treatment given at inclusion (ciclosporin (CsA) in A and 
infliximab (IFX) in B). 
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Among the 55 patients who started infliximab at inclusion (figure 1B), there were 27 failures, 26 successes, 1 
lost to follow-up and 1 severe adverse event leading to treatment interruption (who underwent colectomy after 4 
months) in the initial study. Among the 27 failures, 9 patients underwent directly colectomy after 0.7 (0.2-2.2) 
months, 11 received rescue therapy (4 ciclosporin and 7 infliximab—5 mg/kg in 3 and 10 mg/kg in 4) at 0.9 (0.6-
2.0) months and 7 did not receive rescue therapy. Concerning the four patients who received ciclosporin, two 
underwent colectomy 0.3 and 0.9 months after rescue and two reached end of follow-up 25 and 61 months, the 
latter was subsequently treated by infliximab 50 months after rescue. Among the seven patients who received 
infliximab rescue therapy, four underwent colectomy after 0.2 to 3.3 months, and three reached end of follow-up 
65 to 70 months later. Among the seven patients with infliximab failure who did not received rescue therapy, 
three had new systemic treatment 49 to 66 months after inclusion: one who received steroids and an 
experimental drug underwent colectomy 11 months later, one received steroids and infliximab and one received 
adalimumab reached end of follow-up 16 and 3 months after treatment. The four remaining patients had no new 
treatment and reached end of follow-up 59 to 92 months after inclusion. Among the 26 patients treated with no 
treatment failure at the end of the study period, various infliximab maintenance regimens were given (infliximab 
alone in 2, azathioprine alone in 7 and combotherapy in 17): 17 patients reached end of follow-up 73 (62-83) 
months after inclusion, 1 underwent colectomy 9 months after inclusion and 8 received new systemic treatment 
24 (18-48) months after inclusion (2 underwent colectomy after 1 and 34 months after new treatment despite 
infliximab or adalimumab, 6 received various medical therapies—1 infliximab, 2 steroids, 1 steroids then 
adalimumab, 1 adalimumab, 1 azathioprine—and were still followed up 29 (20-47) months later). Ten patients 
needed an infliximab intensification by shortening interval and/or increasing dose that was a failure in seven 
patients (four underwent colectomy, two switched to adalimumab and one was included in a trial) and successful 
in three. 
Death and colectomy 
Three patients died during the follow-up period: a male aged 66 years who received ciclosporin died from 
myocardial infarction 4 months after inclusion in the trial, a male aged 55 years treated successively with 
ciclosporin and infliximab died from pancreatic adenocarcinoma 21 months after inclusion and a female aged 69 
years exposed to ciclosporin died from non-specified reasons 29 months after enrolment. 
At follow-up update, 39 patients underwent colectomy: 19 treated initially with ciclosporin and 20 with 
infliximab. Colectomy-free survival rates at 1, 2 and 5 years according to treatment given at inclusion were, 
respectively, 70.9% (95% CI 59.2% to 82.6%), 65.3% (95% CI 53.0% to 77.7%) and 61.5% (95% CI 48.7% to 
74.2%) in patients who received ciclosporin and 69.1% (95% CI 56.9% to 81.3%), 67.3% (95% CI 54.9% to 
79.7%) and 65.1% (95% CI 52.4% to 77.8%) in those who received infliximab (HR (95% CI) 0.99 (0.49 to 
1.98); p = 0.97) (figure 2). Among the 39 patients who underwent colectomy, 31 (79%) had pouch surgery—in 
three steps in 19 cases—3 (8%) an ileorectal anastomosis and the remaining 5 (13%) a permanent stoma. Ten 
(26%) patients experienced postoperative complications within the 30 days after colectomy, including four 
infections, three bleedings and two occlusions and one cardiac failure. 
UC medical treatment 
Cumulative incidence of the first additional systemic treatment at 1, 2 and 5 years according to treatment given 
at inclusion was, respectively, 52.6% (95% CI 39.0% to 64.6%), 58.3% (95% CI 44.3% to 70.0%) and 62.3% 
(95% CI 48.1% to 73.7%) in patients who received ciclosporin and 20.0% (95% CI 10.6% to 31.5%), 27.3% 
(95% CI 16.2% to 39.5%) and 36.6% (95% CI 23.9% to 49.3%) in those who received infliximab (ARR (95% 
CI) 0.547 (0.350% to 0.854%); p = 0.011) (figure 3). 
During the follow-up period, 33 patients treated first with ciclosporin and then received infliximab. Cumulative 
incidence of the first use of infliximab at 1, 2 and 5 years in patients first treated with ciclosporin was, 
respectively, 45.7% (95% CI 32.6% to 57.9%), 53.3% (95% CI 39.4% to 65.3%) and 57.1% (95% CI 43.0% to 
69.0%) (figure 4). By contrast, four patients from the infliximab were treated with the converse sequence. 
New UC medical treatment 
When considering new UC therapies given during the follow-up period, we excluded those given at inclusion 
(ciclosporin/infliximab and azathioprine) in the initial study; this definition allows drug discontinuation and 
restart and/or drug optimisation. With this consideration, cumulative incidence of the first use of new UC 
systemic treatment or colectomy at 1, 2 and 5 years was, respectively, 52.6% (95% CI 39.0% to 64.6%), 58.3% 
(95% CI 44.3% to 70.0%) and 62.3% (95% CI 48.1% to 73.7%) in patients who received ciclosporin and 9.1% 
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(95% CI 3.3% to 18.5%), 12.7% (95% CI 5.5% to 23.0%) and 22.0% (95% CI 12.0% to 33.8%) in those who 
received infliximab (ARR (95% CI) 0.273 (0.148 to 0.504); p < 0.001) (figure 5). 
 
Figure 2    Kaplan-Meier curves of colectomy-free survival according to treatment given at inclusion. CsA/Cys, 
ciclosporin; IFX, infliximab. 
 
 
Figure 3    Cumulative incidence of the first use of any additional UC systemic treatment (steroids, ciclosporin, 
infliximab, azathioprine or other biologics) according to treatment given at inclusion. Full line: ciclosporin 




In a multicentre prospective cohort of patients with ASUC refractory to intravenous steroids who were randomly 
assigned for receiving ciclosporin or infliximab as second-line medical therapy, the long-term colectomy-free 
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survival was independent from initial treatment received. However, a higher proportion of patients initially 
treated with ciclosporin required systemic subsequent therapies when compared with those who received 
infliximab first. 
Both treatments have demonstrated their short-term efficacy as rescue therapies after steroid failure in patients 
with ASUC. Intravenous ciclosporin is rapidly and highly effective in this situation, with clinical response rates 
above 80% at 1 week in controlled trials.
7 9 10
 Nevertheless, this great efficacy is counterbalanced by safety 
concerns—such as opportunistic infections, renal dysfunction, high blood pressure or seizures—and is 
decreasing rapidly with time as nearly half of patients will relapse within 1 year despite maintenance therapy 
with thiopurines.
14
 In a cohort of 142 patients with ASUC who received intravenous ciclosporin before the anti-
TNF era, nearly all the patients treated experienced disease relapse and required surgery, with a 5-year 
colectomy rate of 69%.
15
 Such an historical observation contrasts with more recent data with ciclosporin from 
the CONSTRUCT trial and this study showing death/colectomy rates of 48.1% at 3 years
11
 and 38.5% at 5 years, 
respectively. The more favourable outcome after ciclosporin treatment observed in our cohort may be related to 
the selection of patients who were azathioprine-naive and optimal candidates for a bridge strategy. It could also 
be explained by subsequent infliximab use, as observed within the first year in nearly half of the patients. 
Interestingly, 77% of failures in the ciclosporin group occurred within the first year, and infliximab given in this 
situation was well tolerated and provided clinical benefit as approximately half of patients avoided colectomy at 
5 years. 
 




Long-term data on cohorts of inpatients with ASUC treated by infliximab as second-line medical therapy are 
scarce and usually mixing their results with a subgroup of patients having non-severe disease. In the 
CONSTRUCT trial, the 3-year colectomy rate in patients randomised for receiving infliximab was 40.7%,
11
 
comparable to the 34.9% observed at 5 years in the present cohort. 
ASUC mortality rate remains high, around 1%-2% in the most recent series, mainly when colectomy has been 
delayed in elderly patients with comorbidities.
3
 Indeed, deaths were observed in 3/270 (1%) patients in the 
CONSTRUCT trial, all of them treated with infliximab including two postoperative deaths, and in 3/115 (3%) 
patients in the present cohort, all over 50 years and none related to the disease or the immunosuppression. 
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Figure 5    Cumulative incidence of the first use of an additional UC systemic treatment other than those given 
at inclusion. Full line: ciclosporin (CsA). Dotted line: infliximab (IFX). 
 
 
Within the last decade, IBD costs have dramatically increased with the spread of biologics use. In a recent Dutch 
study, anti-TNF are accounting for 31% of costs in UC.
16
 In several countries, direct costs are driving the choice 
between ciclosporin and infliximab in patients with ASUC. If so, and despite a longer duration of hospital stay at 
beginning, 3-month direct costs related to ciclosporin are significantly lower than with infliximab.
17
 Such a cost 
difference between both drugs has been confirmed by the CONSTRUCT trial.
11
 
One of the strengths of this study is the initial randomisation in a well-defined population, providing treatment 
groups comparable at inclusion for baseline characteristic except treatment. This advantage may be slightly 
limited by the analysis according to treatment given instead of allocated, as two patients randomised into the 
infliximab arm received ciclosporin. The second limitation could be the long follow-up duration. Indeed, beyond 
the study period the protective effect of randomisation is decreasing with time as treatment decision is no more 
protocolised and may depend on physician and/or patient. Nevertheless, it should be noted that the clear-cut p 
values for comparing rates for colectomy-free survival and incidence of the first use of new treatment guarantee 
our conclusions. Moreover, the follow-up duration of the present cohort seems appropriate for exploring the 
long-term outcome in patients with ASUC as its median duration was more than 5 years. 
Overall, whatever the drug started as rescue therapy in patients with steroid-refractory ASUC, long-term 
colectomy rates are similar between ciclosporin and infliximab, both drugs having close efficacy and safety. 
Nearly half of patients first treated with ciclosporin will switch quickly to infliximab, within 1 year. 
Accordingly, bridge therapy with ciclosporin to thiopurine was successful in the other half of patients. For daily 
practice, choice between both drugs should not only be guided by efficacy and safety criteria that are close, but 
should also take into account costs, administration route and patient's preference. 
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